Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,042 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,672 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07205497 | QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer(QNACTH) | active not recruiting | Phase 2 | 54 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT02312557 | Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide | active not recruiting | Phase 2 | 58 | OHSU Knight Cancer InstituteOTHER |
| 1 |
| May 14, 2026 |
| clinicaltrials |
| NCT03574571 | A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer | active not recruiting | Phase 3 | 732 | Memorial Sloan Kettering Cancer CenterOTHER | 4 | May 14, 2026 | clinicaltrials |
| NCT04009148 | Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome | active not recruiting | — | 118 | NYU Langone HealthOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04769817 | ProsTIC Registry of Men Treated With PSMA Theranostics | active not recruiting | — | 500 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06970847 | 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer(AMPLIFY) | active not recruiting | Phase 3 | 220 | Clarity Pharmaceuticals LtdINDUSTRY | 2 | May 14, 2026 | clinicaltrials |
| NCT07581873 | Education and Health in Women With Cervical Cancer | active not recruiting | N/A | 28 | Federal University of MaranhaoOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04067713 | Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer(PARADIGM) | active not recruiting | — | 192 | University College, LondonOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT04314401 | National Cancer Institute "Cancer Moonshot Biobank" | active not recruiting | — | 1,600 | National Cancer Institute (NCI)NIH | 2 | May 13, 2026 | clinicaltrials |
| NCT05691504 | Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | active not recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT03515993 | Follow-up in Gynecological Cancer Survivors | active not recruiting | — | 1,100 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | May 12, 2026 | clinicaltrials |
| NCT04846478 | Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC | active not recruiting | Phase 1 | 35 | Dana-Farber Cancer InstituteOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05029258 | Biomarkers for Clinical Hypoxia Evaluation in Cervical Cancer(Bio-CHECC) | active not recruiting | — | 30 | University of ManchesterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04262154 | Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | active not recruiting | Phase 2 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04384770 | CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study | active not recruiting | — | 179 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04486755 | Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) | active not recruiting | Phase 1 | 18 | University of Maryland, BaltimoreOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04502602 | Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer(iNNOVATE) | active not recruiting | Phase 1 | 18 | Virginia Commonwealth UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT01368588 | Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer | active not recruiting | Phase 3 | 2,590 | Radiation Therapy Oncology GroupNETWORK | 6 | May 8, 2026 | clinicaltrials |
| NCT03637543 | Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer | active not recruiting | Phase 2 | 29 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03932409 | Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer(FIERCE) | active not recruiting | Phase 1 | 45 | University of OklahomaOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05826509 | SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer(SUGAR) | active not recruiting | Phase 2 | 240 | Institut Claudius RegaudOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04713618 | Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy(GEORGIA) | active not recruiting | — | 72 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06790004 | Endometrial Carcinoma: Comparison of Surgical Approaches (Laparoscopy vs Laparotomy)(LPSvsLPT) | active not recruiting | — | 700 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | May 7, 2026 | clinicaltrials |
| NCT00579072 | The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older | active not recruiting | — | 230 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT02446444 | Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer(ENZARAD) | active not recruiting | Phase 3 | 802 | University of SydneyOTHER | 9 | May 6, 2026 | clinicaltrials |
| NCT04136353 | Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate(DASL-HiCaP) | active not recruiting | Phase 3 | 1,100 | University of SydneyOTHER | 6 | May 6, 2026 | clinicaltrials |
| NCT04553133 | PF-07104091 as a Single Agent and in Combination Therapy | active not recruiting | Phase 2 | 157 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT06212583 | High-Risk Metachronous Oligometastatic Prostate Cancer Trial(KNIGHTS) | active not recruiting | Phase 2 | 88 | University of Maryland, BaltimoreOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT01411345 | MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial(MAPS) | active not recruiting | N/A | 37 | University of MiamiOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03217747 | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 173 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04430699 | Cisplatin+Pembrolizumab+RT in Vulvar Cancer | active not recruiting | Phase 2 | 24 | Massachusetts General HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05173987 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | active not recruiting | Phase 3 | 280 | Merck Sharp & Dohme LLCINDUSTRY | 27 | May 5, 2026 | clinicaltrials |
| NCT05271318 | Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.(PROTA) | active not recruiting | Phase 1 / Phase 2 | 29 | TILT Biotherapeutics Ltd.INDUSTRY | 2 | May 5, 2026 | clinicaltrials |
| NCT01737619 | PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer | active not recruiting | N/A | 101 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03393884 | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)(OVATION 2) | active not recruiting | Phase 1 / Phase 2 | 130 | ImunonINDUSTRY | 2 | May 4, 2026 | clinicaltrials |
| NCT03772834 | Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer | active not recruiting | Phase 2 / Phase 3 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04753086 | Patient Related Outcomes for Gynecologic Radiation Oncology(PRO-GRO) | active not recruiting | — | 100 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04927650 | Prevention and Early Detection of Cervical Cancer Through Self-Administered Screening | active not recruiting | — | 2,556 | University of California, San FranciscoOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05851365 | Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer | active not recruiting | Early Phase 1 | 1 | Robert Flavell, MD, PhDOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT06651632 | WATER IV Prostate Cancer(WATER IV PCa) | active not recruiting | N/A | 280 | PROCEPT BioRoboticsINDUSTRY | 7 | May 4, 2026 | clinicaltrials |
| NCT04194554 | A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer(ASCLEPIuS) | active not recruiting | Phase 1 / Phase 2 | 102 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04200443 | Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma | active not recruiting | Phase 2 | 96 | City of Hope Medical CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05322356 | Prostate Interstitial Brachytherapy With I125 Implant With Target Dose Supplementation in the Tumor Volume Guided by TRINITY® PERINE 3D System(FOCUS-BOOST) | active not recruiting | N/A | 15 | University Hospital, GrenobleOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05946993 | Linking In With Advice and Supports for Men Impacted by Metastatic Cancer(LIAM Mc) | active not recruiting | N/A | 72 | University College CorkOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06180733 | Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer(PAM-II) | active not recruiting | Phase 2 | 12 | University Medical Center GroningenOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT01068249 | Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04597411 | Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer | active not recruiting | Phase 1 | 101 | EndocyteINDUSTRY | 2 | Apr 30, 2026 | clinicaltrials |
| NCT06628388 | Nurse-led Primary Healthcare Intervention Model in Women's Health Management in Hong Kong(JCDATAZONEWH) | active not recruiting | N/A | 1,728 | The University of Hong KongOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07117760 | Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 16 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07555639 | An Integrated Genomic Approach to Assess Genetic Risk and Drug Sensitivity(GERSOM) | active not recruiting | N/A | 4,000 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2026source: clinicaltrials